EICHORCondition: Advanced Solid Tumor · Sponsor: OncoC4, Inc.
This is a Phase I/II open label study of intravenous (IV) infusion of ONC-841 as a single agent or in combination in patients with advanced/metastatic solid tumors. The study will evaluate seven dose levels of ONC-841. The Phase 1 part is dose escalation with 7 dose levels of ONC-841 and the dose expansion in the last dose level. The Phase 2 part will test the combination of ONC-841 with SOC in GBM and in CRC.
This description comes directly from the study's public registry record.
Pan Zheng, MD, PhD · (240) 552-5193 · pzheng@oncoc4.com
Imaan Khan, MD · ikhan@oncoc4.com
Always discuss trial participation with your own doctor first.
| University of California at Davis Cancer Center | Sacramento, California, United States | Recruiting |
| UF Health Cancer Center, University of Florida | Gainesville, Florida, United States | Recruiting |
| AdventHealth Medical Group Oncology Research at Celebration | Kissimmee, Florida, United States | Recruiting |
| Norton Cancer Center | Louisville, Kentucky, United States | Recruiting |
| Rogel Cancer Center, University of Michigan | Ann Arbor, Michigan, United States | Recruiting |
| Thomas Jefferson University Hospital | Philadelphia, Pennsylvania, United States | Recruiting |
| MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| Huntsman Cancer Institute, University of Utah | Salt Lake City, Utah, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06352359